Soochow University

Everest Medicines Announces Commercial Launch and First Prescription for XERAVA® in China

Retrieved on: 
Thursday, July 27, 2023
Vaccine, Neutropenia, VRE, Fungal infection, Eravacycline, Infection, Fever, New Drug Application, MRSA, Gram-negative bacteria, NDA, Urinary tract infection, First Affiliated Hospital of Xinjiang Medical University, Hematopoietic stem cell transplantation, Soochow University, Incidence, MDR, Radiation, HKEX, Patient, National Medical Products Administration, Huashan Hospital, Fudan University, IgA nephropathy, CRE, NMPA, Pharmaceutical industry, Mount Everest

SHANGHAI, July 26, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced today XERAVA® (eravacycline) has been successfully launched in China with its first prescription issued at Huashan Hospital affiliated to Fudan University. The commercialization of XERAVA® in China marks Everest's transformation into a commercial-stage innovative biopharmaceutical company.

Key Points: 
  • "The commercialization of XERAVA® in China is a significant milestone for Everest as a company, as this marks the beginning of Everest as a commercial-stage biopharma company.
  • I want to thank everyone involved in bringing XERAVA® to a successful launch," said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines.
  • "After the commercial launch, we will accelerate patient access to XERAVA® with a lean commercial team, following a highly efficient commercial strategy.
  • The launch of eravacycline in China will help doctors tackle the challenges of clinical drug resistance."

CELL WORLD - Aiming at Internationalization, Starting from Regulation - The 1st Global Cell Therapy Summit and Hillgene Biopharma Anniversary Celebration Successfully Held

Retrieved on: 
Monday, May 29, 2023
Laughter, European Medicines Agency, Tisagenlecleucel, First Affiliated Hospital of Xinjiang Medical University, Soochow University, Patient, Shanghai University, Cell, Medicines and Healthcare products Regulatory Agency, BLA, BioValley, DLBCL, Duke University School of Medicine, EMA, CELL, Anniversary Celebration, FDA, IND, Multimedia, China Institute for Innovation and Development Strategy, Therapy, MD Anderson Cancer Center, RMB, MHRA, Speech, CMC, Medication, Bristol Myers Squibb, Implementation, CDMO, Clinical trial, Novartis, IBLA International Competition, DoubleTree, Bengbu Medical College, Pharmaceutical industry, Medical device, EU, Medicine

SUZHOU, China, May 29, 2023 /PRNewswire/ -- On May 26, 2023, the "CELL WORLD 1st Global Cell Therapy Summit and Hillgene Biopharma Anniversary Celebration," meticulously planned by Hillgene Biopharma and Biovalley, was successfully held at the DoubleTree by Hilton in Wuzhong District, Suzhou.

Key Points: 
  • SUZHOU, China, May 29, 2023 /PRNewswire/ -- On May 26, 2023, the "CELL WORLD 1st Global Cell Therapy Summit and Hillgene Biopharma Anniversary Celebration," meticulously planned by Hillgene Biopharma and Biovalley, was successfully held at the DoubleTree by Hilton in Wuzhong District, Suzhou.
  • "This is the 1st summit of CELL WORLD, and Hillgene Biopharma will host this summit in the long term.
  • I hope this 1st CELL WORLD Global Cell Therapy Summit will further promote the development and innovation of cell therapy industry globally and provide more thoughts and practical examples."
  • The "CELL WORLD 1st Global Cell Therapy Summit and Hillgene Biopharma Anniversary Celebration" came to a perfect end amid the laughter and joy of the banquet.

MOGU Announces Resignation and Appointment of Directors

Retrieved on: 
Friday, April 21, 2023
Fashion, Online Retail, Retail, Luxury, Other Retail, Technology, Electronic Commerce, American Association of Advertising Agencies, Communication, Advertising, Jiangsu Normal University, Marketing, Consultant, Soochow University, Attention, Limited, Shenzhen, Zhejiang University, Professional Football Compensation Committee, New York Stock Exchange, Mathematics, Annual report, NYSE, Compensated emancipation, Convenience food, Management

MOGU Inc. (NYSE: MOGU) (“MOGU” or the “Company”), a KOL-driven online fashion and lifestyle destination in China, announced that:

Key Points: 
  • MOGU Inc. (NYSE: MOGU) (“MOGU” or the “Company”), a KOL-driven online fashion and lifestyle destination in China, announced that:
    Mr. Yibo Wei (“Mr.
  • The Company opts to follow its home country practice in lieu of the requirement under NYSE Section 303A.05(a) to have a compensation committee comprised entirely of independent directors.
  • Mr. Wei and Mr. Yue played critical roles in forging MOGU into the vibrant company it is today.
  • MOGU Inc. (NYSE: MOGU) is a KOL-driven online fashion and lifestyle destination in China.

MOGU Announces Resignation and Appointment of Chief Executive Officer

Retrieved on: 
Friday, March 17, 2023
Fashion, Online Retail, Retail, Luxury, Other Retail, Technology, Electronic Commerce, American Association of Advertising Agencies, Communication, Advertising, Jiangsu Normal University, Marketing, Soochow University, Attention, Growth, New York Stock Exchange, NYSE, Management, Mogujie

MOGU Inc. (NYSE: MOGU) (“MOGU” or the “Company”), a KOL-driven online fashion and lifestyle destination in China, announced the resignation of Mr. Qi Chen (“Mr.

Key Points: 
  • MOGU Inc. (NYSE: MOGU) (“MOGU” or the “Company”), a KOL-driven online fashion and lifestyle destination in China, announced the resignation of Mr. Qi Chen (“Mr.
  • Chen”) as the Chief Executive Officer of the Company (the “CEO”) due to personal reasons, effective March 17, 2023.
  • Mr.
  • Mr.

Writepath Has Raised A New Round Of Investment From Elite Investor

Retrieved on: 
Monday, December 19, 2022
IR, MZ, DeepL Translator, B2B, Assistant, Advertising, Documentation, Greater, Printing, Disclosure, Marketing, Language, Reading, RR Donnelley, Richard Slator Dunn, Ecosystem, AGM, Taipei City Government, Taipei, FiscalNote, Multimedia, Directive 2014/65/EU, SDL, Soochow University, Multilingualism, United, Research, Watson (computer), AI, ESG, QIC, Security (finance), Cryptocurrency, Online shopping, Pronexus

TAIPEI, Dec. 19, 2022 /PRNewswire/ -- WritePath is proud to announce a new round of investment from prestigious investor.

Key Points: 
  • TAIPEI, Dec. 19, 2022 /PRNewswire/ -- WritePath is proud to announce a new round of investment from prestigious investor.
  • Prior to this round of fund-raising, WritePath previously received investment by UDN.com, a subsidiary of Taiwan's United Daily News Group, and well-known Singaporean translation firm Elite Asia.
  • WritePath also continues to recruit people who are passionate about language, corporate governance transparency/ESG-related regulations, and English-language information disclosure.
  • We have a wide network of contacts within local industry and in the international investment community.

Meihua International Medical Technologies Co., Ltd. Appoints New CEO, CFO and Directors

Retrieved on: 
Monday, December 5, 2022
UC, Morgan Stanley, III, Partnership, Certification, Actuarial science, The Company, Computer science, II, Public sector banks in India, Giant Panda (group), Yangzhou University, CPA, CFO, History of the University of California, Santa Barbara, ISO, Research, Hospital, Employment, FDA, Pharmacy, Citibank, Governance and Economic Management Assistance Program, Growth, University, Soochow University, Marketing, Mask, University of California, Santa Barbara, Management, Security (finance), PRC

Mr. Wang obtained his bachelor's degree from the University of California Santa Barbara, where he double majored in Financial Mathematics & Statistics Analysis and Computer Science.

Key Points: 
  • Mr. Wang obtained his bachelor's degree from the University of California Santa Barbara, where he double majored in Financial Mathematics & Statistics Analysis and Computer Science.
  • Prior to his appointment at MHUA, Mr. Lianzhang Zhao was Senior Partner at Yangzhou Hanrui Accounting Firm from 2013 to 2022.
  • About Meihua International Medical Technologies Co., Ltd.
    Meihua International Medical Technologies is a reputable manufacturer and provider of Class I, II, and III disposable medical devices with operating subsidiaries in China.
  • For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release.

Innovent Announced Clinical Data of Multiple Trials Will be Presented at the 2022 ESMO-IO and ASH Annual Meetings

Retrieved on: 
Monday, November 28, 2022
Autoimmune disease, Autoimmunity, Metastasis, Environment, CML, Medicine, Nature, NSCLC, Selpercatinib, Metabolic disorder, Hospital, Chemistry, CMC, Soochow University, TKI, Eli Lilly and Company, Mutation, First Affiliated Hospital of Xinjiang Medical University, Eli Lilly, Trial of the century, Ophthalmology, Peking Union Medical College, Ramucirumab, HKEX, Control, News, Tolerability, NDA, Efficacy, Cancer, Social conditions in Honduras, Integrity, Stock exchange, Main, MD Anderson Cancer Center, Sintilimab, Bevacizumab, The First Affiliated Hospital of Wenzhou Medical University, NMPA, Motherboard, Vaccine, Management, Pharmaceutical industry, Patient, Safety, Spotlight Innovation, Hematology, Incyte

On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.

Key Points: 
  • On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.
  • Since its inception, Innovent has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities.
  • An additional 2 assets are under NMPA NDA review, 5 assets are in Phase 3 or pivotal clinical trials, and 20 more molecules are in clinical studies.
  • Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts.

2022 Yidan Prize - world's highest accolade in education - awarded to Dr Linda Darling-Hammond and Professor Yongxin Zhu

Retrieved on: 
Thursday, September 29, 2022
Linda, Board of directors, OECD, UNESCO, Policy, NEI, Soochow University, Directorate, Secondary research, Public policy, Learning, UNESCO Institute for Lifelong Learning, Education Development Center, CEO, Geography, Student, Prize, Reading, Science, Information, School, Stanford University, Research, Teacher, Multimedia, Communication, School of education, Tutoring, Pharmaceutical industry, Yidan Prize, Education

HONG KONG, Sept. 28, 2022 /PRNewswire/ -- The Yidan Prize Foundation has awarded Dr Linda Darling-Hammond and Professor Yongxin Zhu the 2022 Yidan Prize, the world's highest education accolade.

Key Points: 
  • HONG KONG, Sept. 28, 2022 /PRNewswire/ -- The Yidan Prize Foundation has awarded Dr Linda Darling-Hammond and Professor Yongxin Zhu the 2022 Yidan Prize, the world's highest education accolade.
  • Following a rigorous independent judging process, Dr Linda Darling-Hammond and Professor Yongxin Zhu receive the 2022 Yidan Prize for Education Research and the 2022 Yidan Prize for Education Development, respectively.
  • "We offer our warmest congratulations to our 2022 Yidan Prize laureates, Dr Linda Darling-Hammond and Professor Yongxin Zhu.
  • Professor Yongxin Zhu, Founder of the New Education Initiative (NEI) and Professor, School of Education, Soochow University, is awarded the 2022 Yidan Prize for Education Development for his work in improving teaching quality and transforming learning outcomes in China.

2022 Yidan Prize - world's highest accolade in education - awarded to Dr Linda Darling-Hammond and Professor Yongxin Zhu

Retrieved on: 
Thursday, September 29, 2022
Linda, Board of directors, OECD, UNESCO, Policy, NEI, Soochow University, Directorate, Secondary research, Public policy, Learning, UNESCO Institute for Lifelong Learning, Education Development Center, CEO, Geography, Student, Prize, Reading, Science, Information, School, Stanford University, Research, Teacher, Communication, Tutoring, Pharmaceutical industry, Yidan Prize, Education

HONG KONG, Sept. 29, 2022 /PRNewswire/ -- The Yidan Prize Foundation has awarded Dr Linda Darling-Hammond and Professor Yongxin Zhu the 2022 Yidan Prize, the world's highest education accolade.

Key Points: 
  • HONG KONG, Sept. 29, 2022 /PRNewswire/ -- The Yidan Prize Foundation has awarded Dr Linda Darling-Hammond and Professor Yongxin Zhu the 2022 Yidan Prize, the world's highest education accolade.
  • Following a rigorous independent judging process, Dr Linda Darling-Hammond and Professor Yongxin Zhu receive the 2022 Yidan Prize for Education Research and the 2022 Yidan Prize for Education Development, respectively.
  • "We offer our warmest congratulations to our 2022 Yidan Prize laureates, Dr Linda Darling-Hammond and Professor Yongxin Zhu.
  • Professor Yongxin Zhu, Founderof theNew Education Initiative (NEI) and Professor, Schoolof Education, Soochow University, is awarded the 2022 Yidan Prize for Education Development for his work in improving teaching quality and transforming learning outcomes in China.

Halomine, Inc. Announces the Appointment of Dr. Xeuhong Ren as Chief Scientific Officer, Three New Board Members

Retrieved on: 
Wednesday, November 3, 2021
Infectious Diseases, Chemicals, Plastics, Manufacturing, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, MSE, Polymer, University of South Dakota, Fungus, Cornell University, Biotechnology, Technology, University, Soochow University, Industry, Government Institute of Textile Chemistry and Knitting Technology, NewYork-Presbyterian Hospital, Virus, Independent, Biofilm, BSE, Hospital, Board, CEO, Chemical engineering, Bacteria, National Science Advisory Board for Biosecurity, Solution, Auburn University, Therapy, D, Princeton University, Chemistry, Doctor of Philosophy, Wharton School of the University of Pennsylvania, Science Advisory Board, Board of directors, Management

Ted Eveleth, CEO of Halomine said We are pleased to welcome Dr. Ren and our new board members.

Key Points: 
  • Ted Eveleth, CEO of Halomine said We are pleased to welcome Dr. Ren and our new board members.
  • Dr. Ren is a distinguished world class scientist, and our new Board members bring a wealth of experience to our efforts.
  • Dr. Xuehong Ren , one of the worlds leading authorities on synthesized monomers and polymers and n-Halomine chemistries, has joined Halomine Inc. as Chief Scientific Officer.
  • Dr. Ren is the inventor of over twenty patents and the author of over 150 peer-reviewed journal articles.